Clay Siegall helped to co-found Seattle Genetics, and he has commented on the fact that the idea for the company came from watching his dad live with cancer for years until he died. It was difficult for him to watch as there was not much that could be done about the cancer. This inspired him to learn how to improve upon the tools physicians and others have on-hand to battle the disease, and he studied genetics during his college years to begin his journey. It his goal to create targeted drugs that can do more than the drugs of the past, and he is inspired every day to continue his work.
When asked if there has been a strategy that has helped him to grow his business, Clay Siegall commented that he has learned how important it is to collaborate with other leaders and innovative people in the industry and that this has helped Seattle Genetics to be able to reach a larger market through the technology they create. This has been a huge help with freeing up the time of the innovators within his own company so they can work on new ideas.
Clay Siegall is the co-founder of Seattle Genetics who helped to put the company together in 1998. He now serves as the company’s President, Chairman of the Board, and Chief Executive Office and works on developing antibody-drug conjugates (ADCs). One of the drugs that Siegall has helped to get FDA approval for is known as ADCETRIS, and this drug is now being distributed globally. Siegall has been responsible for helping Seattle Genetics to earn more than $350 million through ADC tech.
Clay Siegall has worked hard over the years to generate capital for his company through capital-raising actions that have secured over $1.2 billion. Before he came aboard with Seattle Genetics, he worked with the Bristol-Meyers Squibb Pharmaceutical Research Institute and also the the National Cancer Institute, National Institutes of Health. He received his Bachelor’s of Science Degree in Zoology during his time spent at the University of Maryland and his Ph.D in Genetics while attending the George Washington University.
Find out more about Clay Siegall: http://www.bizjournals.com/seattle/blog/health-care-inc/2016/03/seattle-genetics-ambitious-plan-for-12-more-drugs.html